Vera Therapeutics
NASDAQ · VERA·Brisbane, CA·Mid-cap·Phase 3
Clinical-stage immunology biotech developing atacicept, a dual BAFF/APRIL inhibitor in Phase 3 ORIGIN for IgA nephropathy. Pipeline also includes MAU868 (anti-BKV antibody) for transplant recipients.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Vera Therapeutics Corporate Deck April 2026 | Corporate overview | April 13, 2026 | 32 |